الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
This study was designed to find out the suitable range of blood glucose level in head trauma patients and the possible benefits and risks of tight glycemic control in this group of patients. We assumed that intermediate control of blood glucose (110-140 mg.dl-1) will be a reasonable option to protect the brain injured patients from the possible hazards of hypoglycemic episodes of TGC.
This study was carried out on patients with severe traumatic brain injury (GCS≤8).They were randomly divided into 2 major groups via sealed envelope assignment׃ GroupT (tight glycemic group) with random blood sugar between 80-110 mg.dl-1 (129 patients) and groupI (intermediate glycemic group) with random blood sugar between 110-140 mg.dl-1 (124 patients).
The main outcome measures in this study were׃ GCS, GOS, incidence of hypoglycemic episodes and number of patients who developed one or more episodes of hypoglycemia were considered as the primary end point of the study. Incidence of infection, vital organ dysfunction development that needed support, patients needed mechanical ventilation for more than 48 hours, ICU stay and 28-day mortality were considered as secondary end point of the study.
Intermediate glycemic control with random blood sugar between 110-140 mg.dl-1 recorded lower incidence of hypoglycemic episodes, days of ventilation and period of stay in ICU compared with tight glycemic control with lower range between 80-110 mg.dl-1 regarding patients with severe TBI. In spite of that their was no significant difference regards infection and the need for vital organ support between both groups, we observed that this intermediate range recorded significant improvement in Glasgow outcome score with lower 28 day mortality.
Finally, we concluded that tight glycemic control ranging between 80-110 mg.dl-1 did not offer any advantage over intermediate glycemic control with random blood sugar ranging between 110-140 mg.dl-1 in patients with severe TBI.